Cim Investment Mangement Inc. Purchases 2,964 Shares of Integra Lifesciences Holdings Corp (IART)

Cim Investment Mangement Inc. increased its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 42.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,965 shares of the life sciences company’s stock after buying an additional 2,964 shares during the period. Cim Investment Mangement Inc.’s holdings in Integra Lifesciences were worth $551,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Integra Lifesciences by 38.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock valued at $182,000 after purchasing an additional 1,054 shares in the last quarter. Stanley Laman Group Ltd. acquired a new position in Integra Lifesciences in the first quarter valued at approximately $221,000. Zions Bancorporation acquired a new position in Integra Lifesciences in the first quarter valued at approximately $235,000. Quantitative Systematic Strategies LLC acquired a new position in Integra Lifesciences in the first quarter valued at approximately $270,000. Finally, Xact Kapitalforvaltning AB acquired a new position in Integra Lifesciences in the fourth quarter valued at approximately $311,000. Hedge funds and other institutional investors own 79.47% of the company’s stock.

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. upped their price target on Integra Lifesciences from $57.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday. Zacks Investment Research raised Integra Lifesciences from a “hold” rating to a “buy” rating and set a $69.00 price objective for the company in a report on Tuesday, May 1st. Morgan Stanley increased their price objective on Integra Lifesciences from $53.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, April 26th. ValuEngine raised Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Friday, April 27th. Finally, Oppenheimer set a $70.00 price objective on Integra Lifesciences and gave the company a “buy” rating in a report on Tuesday, May 1st. Eleven research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $59.85.

Shares of Integra Lifesciences opened at $63.99 on Thursday, according to Marketbeat. The company has a debt-to-equity ratio of 1.77, a current ratio of 2.53 and a quick ratio of 1.66. Integra Lifesciences Holdings Corp has a 1-year low of $41.51 and a 1-year high of $65.32. The firm has a market cap of $5.67 billion, a P/E ratio of 32.98, a P/E/G ratio of 1.94 and a beta of 0.66.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, April 25th. The life sciences company reported $0.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.09. Integra Lifesciences had a return on equity of 17.90% and a net margin of 5.39%. The firm had revenue of $357.10 million during the quarter, compared to the consensus estimate of $349.15 million. During the same period last year, the company earned $0.39 earnings per share. The company’s revenue for the quarter was up 38.1% on a year-over-year basis. sell-side analysts predict that Integra Lifesciences Holdings Corp will post 2.41 earnings per share for the current fiscal year.

In related news, VP Daniel L. Reuvers sold 1,000 shares of the stock in a transaction on Monday, April 30th. The stock was sold at an average price of $62.04, for a total transaction of $62,040.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christian S. Schade sold 15,658 shares of the stock in a transaction on Monday, March 5th. The stock was sold at an average price of $52.88, for a total value of $827,995.04. Following the sale, the director now directly owns 75,262 shares of the company’s stock, valued at $3,979,854.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 80,765 shares of company stock valued at $4,376,248. Corporate insiders own 5.10% of the company’s stock.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply